Evidence map›Paper›PMID 34013263›Full record

ArticlebioRxiv : the preprint server for biology2021

Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19.

Paulina Kaplonek, Chuangqi Wang, Yannic Bartsch, Stephanie Fischinger, Matthew J Gorman, Kathryn Bowman, Jaewon Kang, Diana Dayal, Patrick Martin, Radoslaw Nowak and 14 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 15 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 1 country.

Paulina Kaplonek *Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Chuangqi Wang *Department of Biological Engineering, Massachusetts Institute of Technology, MA, USA.
Yannic BartschRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Stephanie FischingerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Matthew J GormanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Kathryn BowmanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Jaewon KangRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Diana DayalSpace Exploration Technologies Corp, USA.
Patrick MartinSpace Exploration Technologies Corp, USA.
Radoslaw NowakMassachusetts General Hospital, USA.
Ching-Lin HsiehRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Jared FeldmanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Boris JulgRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Eric J NillesBrigham Women's Hospital, USA.
Elon R MuskSpace Exploration Technologies Corp, USA.
Anil S MenonSpace Exploration Technologies Corp, USA.
Eric S FischerMassachusetts General Hospital, USA.
Jason S McLellanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Aaron SchmidtRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Marcia B GoldbergMassachusetts General Hospital, USA.
Michael FilbinMassachusetts General Hospital, USA.
Nir HacohenRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, MA, USA.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Ragon Institute of MGH, MIT and Harvard · USMassachusetts General Hospital · USSpaceX (United States) · USBroad Institute · USMassachusetts Institute of Technology · USBrigham and Women's Hospital · US

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2018 to 2026
$32.0M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
SARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3M
CHLAMYDIA PNEUMONIAE AND MACROPHAGES IN ATHEROSCLEROSISR01AI042790 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI BYRNE, GERALD IRWIN · 1999 to 2003
$983k
NCI NIH HHS U01 CA260476NIAID NIH HHS 75N93019C00052NIAID NIH HHS R01 AI042790NIAID NIH HHS R01 AI146785NIAID NIH HHS R37 AI080289NIAID NIH HHS U19 AI135995
6 · The paper itself

Abstract

The introduction of vaccines has inspired new hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against COVID-19, thus we profiled the earliest humoral signatures in a large cohort of severe and asymptomatic COVID-19 individuals. While a SARS-CoV-2-specific immune response evolved rapidly in survivors of COVID-19, non-survivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibody evolution. Given the conservation of S2 across β-coronaviruses, we found the early development of SARS-CoV-2-specific immunity occurred in tandem with pre-existing common β-coronavirus OC43 humoral immunity in survivors, which was selectively also expanded in individuals that develop paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.

Identifiers

PMID34013263
PMCPMC8132219
OpenAlexW3163013828

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.